If in non-pacemaker cells: Role and pharmacological implications

Pharmacological Research

Volumn 53, Issue 5, 2006, Pages 416-423

  Cerbai, Elisabetta ^a   Mugelli, Alessandro ^a  

^a Department of Preclinical and Clinical Pharmacology   (Italy)

Author keywords

Heart failure; If inhibitors; Pacemaker current

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED ION CHANNEL; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED ION CHANNEL 2; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED ION CHANNEL 4; ION CHANNEL; IRBESARTAN; ISOPRENALINE; IVABRADINE; LOSARTAN; NORADRENALIN; SEROTONIN; SEROTONIN 4 ANTAGONIST; UNCLASSIFIED DRUG; ZATEBRADINE;

ARRHYTHMOGENESIS; ARTICLE; CARDIOVASCULAR RISK; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HEART ATRIUM; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PACEMAKER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINOATRIAL CONDUCTION; UPREGULATION;

ANIMALS; HEART ATRIA; HEART DISEASES; HEART RATE; HEART VENTRICLES; HUMANS; ION CHANNELS; MYOCYTES, CARDIAC; VENTRICULAR REMODELING;

EID: 33646598103     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.03.015     Document Type: Article

References (57)

1. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 53 (2006) 399-406
2. Barbieri M., Varani K., Cerbai E., Guerra L., Li Q., Borea P.A., et al. Electrophysiological basis for the enhanced cardiac arrhythmogenic effect of isoprenaline in aged spontaneously hypertensive rats. J Mol Cell Cardiol 26 (1994) 849-860
3. Cerbai E., Pino R., Sartiani L., and Mugelli A. Influence of postnatal-development on if occurrence and properties in neonatal rat ventricular myocytes. Cardiovasc Res 42 (1999) 416-423
4. f current and spontaneous activity in mouse embryonic ventricular myocytes. Circ Res 88 (2001) 536-542
5. f, in rat ventricle cells. Pflugers Arch 433 (1997) 533-535
6. Abi-Gerges N., Ji G.J., Lu Z.J., Fischmeister R., Hescheler J., and Fleischmann B.K. Functional expression and regulation of the hyperpolarization activated non-selective cation current in embryonic stem cell-derived cardiomyocytes. J Physiol (London) 523 (2000) 377-389
7. f, in ventricular myocytes isolated from hypertensive rats. J Physiol (London) 481 (1994) 585-591
8. f in ventricular myocytes from normotensive and hypertensive rats during aging. Circulation 94 7 (1996) 1674-1681
9. Stilli D., Sgoifo A., Macchi E., Zaniboni M., De Iasio S., Cerbai E., et al. Myocardial remodeling and arrhythmogenesis in moderate cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 280 (2001) H142-H150
10. f and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol (London) 553 (2003) 395-405
11. Cerbai E., Sartiani L., De Paoli P., and Mugelli A. Isolated cardiac cells for electropharmacological studies. Pharmacol Res 42 (2000) 1-8
12. Sartiani L., DePaoli P., Stillitano F., Aimond F., Vassort G., Mugelli A., et al. Functional remodeling in post-myocardial infarcted rats: Focus on beta-adrenoceptor subtypes. J Mol Cell Cardiol 40 (2006) 258-266
13. f, in ventricular myocytes from human failing heart. Circulation 95 (1997) 568-571
14. Hoppe U.C., Jansen E., Sudkamp M., and Beuckelmann D.J. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation 97 (1998) 55-65
15. f in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol 33 (2001) 441-448
16. Biel M., Schneider A., and Wahl C. Cardiac HCN channels: structure, function, and modulation. Trends Cardiovasc Med 12 (2002) 206-213
17. Ludwig A., Zong X., Jeglitsch M., Hofmann F., and Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature 393 (1998) 587-591
18. Santoro B., Liu D.T., Yao H., Bartsch D., Kandel E.R., Siegelbaum S.A., et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. Cell 93 (1998) 717-729
19. Shi W., Wymore R., Yu H., Wu J., Wymore R.T., Pan Z., et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 85 (1999) e1-e6
20. Pachucki J., Burmeister L.A., and Larsen P.R. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res 85 (1999) 498-503
21. 2-adrenoceptor overexpressing mice. Naunyn Schmiedebergs Arch Pharmacol 364 (2001) 131-139
22. Borlak J., and Thum T. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J 17 (2003) 1592-1608
23. f) in normal and failing human heart. Circulation 110 Suppl (2004) III-129
24. El Armouche A., Zolk O., Rau T., and Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 60 (2003) 478-487
25. Post S.R., Hammond H.K., and Insel P.A. Beta-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol 39 (1999) 343-360
26. f by β-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats. Cardiovasc Res 42 (1999) 121-129
27. Xiao R.P., Ji X., and Lakatta E.G. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47 (1995) 322-329
28. f by β-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats. Cardiovasc Res 42 (1999) 121-129
29. 1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 108 (2003) 1633-1639
30. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 35 (1989) 295-303
31. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79 (1999) 215-262
32. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
33. Sadoshima J., and Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73 (1993) 413-423
34. Kajstura J., Cigola E., Malhotra A., Li P., Cheng W., Meggs L.G., et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29 (1997) 859-870
35. Henegar J.R., Schwartz D.D., and Janicki J.S. ANG II-related myocardial damage: role of cardiac sympathetic catecholamines and beta-receptor regulation. Am J Physiol Heart Circ Physiol 275 (1998) H534-H541
36. Cerbai E., Crucitti a, Sartiani L., De Paoli P., Pino R., Rodriguez M.L., et al. Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res 45 (2000) 388-396
37. Cerbai E., De Paoli P., Sartiani L., Lonardo G., and Mugelli A. Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. J Cardiovasc Pharmacol 41 (2003) 804-812
38. Stillitano F., DePaoli P., Sartiani L., Paola R., Mugelli A., and Cerbai E. A molecular basis for HCN channel over-expression. Eur Heart J 24 (2003) 131
39. f in human atrial appendage fibres. J Physiol 357 (1984) 125II
40. Heidbuchel H., Vereecke J., and Carmeliet E. The electrophysiological effects of acetylcholine in single human atrial cells. J Mol Cell Cardiol 19 (1987) 1207-1219
41. Thuringer D., Lauribe P., and Escande D. A hyperpolarization-activated inward current in human myocardial cells. J Mol Cell Cardiol 24 (1992) 451-455
42. 1-adenosine receptor stimulation. Br J Pharmacol 122 (1997) 963-969
43. f) in human atrial cells: implications for atrial arrhythmias. Cardiovasc Res 38 (1998) 537-540
44. f to cardiac arrhythmias. Circulation 111 (2005) 399-404
45. Kaumann A.J. 5-HT4-like receptors in mammalian atria. J Neural Transm Suppl 34 (1991) 195-201
46. Bach T., Syversveen T., Kvingedal A.M., Krobert K.A., Brattelid T., Kaumann A.J., et al. 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol 363 (2001) 146-160
47. Blondel O., Gastineau M., Dahmoune Y., Langlois M., and Fischmeister R. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem 70 (1998) 2252-2261
48. 4 receptor splice variants: compound specificity and dual coupling with Galpha s- and Galpha i/o-proteins. Mol Pharmacol 61 (2002) 85-96
49. Venugopal J. Cardiac natriuretic peptides-hope or hype?. J Clin Pharm Ther 26 1 (2001) 15-31
50. f and human atrial arrhythmia. Cardiovasc Res 38 3 (1998) 537-540
51. f) in human atrial myocytes. Cardiovasc Res 63 (2004) 528-536
52. f in human isolated atrial myocytes. Cardiovasc Res 40 (1998) 516-522
53. f) in human atrial myocytes: focus on G protein-coupled receptors. J Mol Cell Cardiol 38 (2005) 453-460
54. 4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 100 (1999) 2010-2017
55. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64 (2004) 1757-1765
56. f channels by ivabradine. J Gen Physiol 120 (2002) 1-13
57. Tomaselli G., and Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42 (1999) 270-283